S Mielke
Overview
Explore the profile of S Mielke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
[Ophthalmic oncology in a warmer world: climate-related increase in the prevalence of eyelid cancer]
Goldammer I, Mielke S, Emmert S, Furashova O, Kakkassery V
Ophthalmologie
. 2025 Jan;
122(1):4-11.
PMID: 39808279
Background: Damage induced by ultraviolet (UV) radiation plays a decisive role in the carcinogenesis of malignant tumors of the eyelids. Methods: A selective literature search was performed in PubMed and...
2.
Hayden P, Roddie C, Bader P, Basak G, Bonig H, Bonini C, et al.
Ann Oncol
. 2021 Dec;
33(3):259-275.
PMID: 34923107
Background: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle...
3.
Lamby P, Wolff D, Mielke S, Grigoleit G, Ljungman P, Hilgendorf I, et al.
Ann Hematol
. 2019 Apr;
98(8):1867-1875.
PMID: 30993415
Refractory skin ulcers due to severe chronic graft-versus-host disease (cGVHD) remain to be associated with significant morbidity and mortality.We performed an allogeneic donor skin transplantation in seven adult patients after...
4.
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S, et al.
Leukemia
. 2015 Aug;
29(10):2062-8.
PMID: 26228813
Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality. Preclinical evidence indicates the potent...
5.
Einsele H, Loffler J, Kapp M, Rasche L, Mielke S, Grigoleit U
Bone Marrow Transplant
. 2015 Jun;
50 Suppl 2:S51-4.
PMID: 26039208
Allogenic stem cell transplantation (allo-SCT) represents the only curative option for several hematological malignancies. Due to a delayed and dysfunctional immunological recovery infectious complications and residual tumor cells following allo-SCT...
6.
Mielke S, Lutz M, Schmidhuber J, Kapp M, Ditz D, Ammer J, et al.
Bone Marrow Transplant
. 2014 Aug;
49(11):1412-8.
PMID: 25089598
Chronic GVHD (cGVHD) remains the most important cause of late non-relapse mortality post allogeneic hematopoietic SCT (HSCT). Although first-line treatment of cGVHD with steroids is well established, evidence for second-line...
7.
Hefner J, Kapp M, Drebinger K, Dannenmann A, Einsele H, Grigoleit G, et al.
Bone Marrow Transplant
. 2014 Jan;
49(4):581-4.
PMID: 24442247
Little is known about the psychological burden patients are left with after successful allogeneic hematopoietic SCT (HSCT). With the main focus on physical condition and common transplant complications, psychological symptoms...
8.
Rasche L, Kapp M, Einsele H, Mielke S
Bone Marrow Transplant
. 2013 Jul;
49(2):163-7.
PMID: 23832092
EBV-induced post transplantation lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after allogeneic hematopoietic cell transplantation. Profound T-cell depletion of the allograft represents a major risk factor for EBV-PTLD. With regard...
9.
Innes A, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D, et al.
Bone Marrow Transplant
. 2013 May;
48(10):1324-8.
PMID: 23686098
Although the feasibility of using HLA-mismatched unrelated donors as an alternate graft source for haematopoietic SCT (HSCT) has been shown, little is known about the safety of HLA-mismatched DLI for...
10.
Venepalli N, Rezvani K, Mielke S, Savani B
Bone Marrow Transplant
. 2010 Jun;
45(11):1579-86.
PMID: 20531284
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML. However, for a minority of patients who fail TKI or progress to advanced phase disease, allo-SCT remains the only therapeutic...